Want to see AU:EMD full AI Analyst Report?
Top Page
Emyria Ltd
(Sydney:EMD)
Select Model
Select Model
Rating:50Neutral
Price Target:
AU$0.05
â–²(30.00% Upside)
Action:Reiterated
Date:09/16/26
The score is held back primarily by weak financial performance: persistent losses, highly negative margins, and ongoing negative operating/free cash flow outweigh the recent revenue rebound. Technicals are moderately positive with the price above key moving averages and a positive MACD, but near-term momentum looks stretched (high Stoch). Valuation is constrained by negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Revenue rebound
Revenue growth of 78.34% in 2026 indicates a meaningful rebound in demand or activity and gives the company a larger base from which to scale its mental-health services and development work. If sustained, this expansion could improve operating leverage over coming quarters.
Negative Factors
Persistent losses
Despite the revenue rebound, Emyria remains loss-making, with 2026 net income of -$6.1M and deeply negative margins, including gross margin. Costs running ahead of revenue indicate limited operating leverage, making sustained profitability dependent on substantial improvement in economics.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound
Revenue growth of 78.34% in 2026 indicates a meaningful rebound in demand or activity and gives the company a larger base from which to scale its mental-health services and development work. If sustained, this expansion could improve operating leverage over coming quarters.
Read all positive factors
Emyria Ltd (EMD) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$37.11M
Dividend YieldN/A
Average Volume (3M)2.02M
Price to Earnings (P/E)―
Beta (1Y)1.21
Revenue Growth178.16%
EPS Growth-15.71%
CountryAU
Employees6
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding806,686,040
10 Day Avg. Volume3,219,338
30 Day Avg. Volume2,015,434
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)3.35
Price to Sales (P/S)7.63
P/FCF Ratio-6.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$9.70M
Emyria Ltd Business Overview & Revenue Model
Company Description
Emyria Limited is a biotechnology firm currently in the clinical stage, dedicated to creating therapies for medical conditions that lack effective treatments. The company's work primarily involves the development of cannabinoid-derived pharmaceuti...
Emyria Ltd Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.88M | 1.39M | 2.20M | 1.59M | 1.82M |
| Gross Profit | -3.66M | 24.48K | -167.55K | -3.32M | -4.41M |
| EBITDA | -5.81M | -2.39M | -13.03M | -6.69M | -8.03M |
| Net Income | -6.11M | -3.14M | -11.46M | -5.13M | -7.33M |
Balance Sheet | |||||
| Total Assets | 11.49M | 6.62M | 5.43M | 10.16M | 8.25M |
| Cash, Cash Equivalents and Short-Term Investments | 7.29M | 3.57M | 1.57M | 2.73M | 3.88M |
| Total Debt | 787.38K | 613.50K | 1.72M | 1.27M | 632.70K |
| Total Liabilities | 2.65M | 1.31M | 3.00M | 3.37M | 1.93M |
| Stockholders Equity | 8.85M | 5.31M | 2.43M | 6.79M | 6.32M |
Cash Flow | |||||
| Free Cash Flow | -4.92M | -2.72M | -4.44M | -7.01M | -7.46M |
| Operating Cash Flow | -4.56M | -2.70M | -4.28M | -3.77M | -5.43M |
| Investing Cash Flow | -546.59K | 81.07K | -1.38M | -3.23M | -2.03M |
| Financing Cash Flow | 8.82M | 4.63M | 4.50M | 5.86M | 4.81M |
Emyria Ltd Technical Analysis
Positive
0.04
Price Trends
0.05
Positive
0.04
Positive
0.05
Positive
Market Momentum
<0.01
Negative
53.58
Neutral
44.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EMD, the sentiment is Positive. The current price of 0.04 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.05, and below the 200-day MA of 0.05, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 53.58 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:EMD.
Emyria Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | AU$586.48M | 33.77 | 21.61% | 1.76% | 6.95% | 10.77% | |
61 Neutral | AU$141.73M | 64.71 | 2.53% | ― | 26.61% | 41.67% | |
60 Neutral | AU$40.33M | 16.72 | 90.90% | ― | 5.35% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$121.68M | -7.18 | -203.69% | ― | -1.53% | 28.29% | |
50 Neutral | AU$37.11M | -5.80 | -58.38% | ― | 178.16% | -15.71% | |
49 Neutral | AU$27.17M | -1.59 | -58.13% | ― | 2.08% | -195.31% |
* Healthcare Sector Average
AU:EMD
Emyria Ltd
0.05
-0.02
-32.35%
AU:CGS
Cogstate Ltd
3.41
1.24
57.07%
AU:ONE
Oneview Healthcare Chess Depository Interests repr 1
0.15
-0.08
-34.78%
AU:BMT
Beamtree Holdings Ltd
0.10
-0.13
-56.52%
AU:ALC
Alcidion Group Limited
0.11
<0.01
10.00%
AU:DOC
Doctor Care Anywhere Group PLC Shs Chess Depository Interests Repr 1 sh
0.12
-0.05
-28.13%
Emyria Ltd Corporate Events
Emyria takes Australian psychedelic treatment model to U.S. FDA
Sep 15, 2026
Emyria Limited, an Australian leader in innovative mental health treatments, specialises in psychedelic-assisted therapy delivered through regulated clinical settings. The company has built comprehensive capabilities across governance, training, i...
Emyria flags safety risks and regulatory hurdles for experimental psychedelic therapies
Sep 7, 2026
Emyria’s latest investor update reiterates that its pipeline of MDMA, psilocybin and MDMA-inspired therapies remains at an experimental stage, with no products yet approved by Australia’s Therapeutic Goods Administration. The company s...
Emyria Doubles Revenue but Posts Wider Annual Loss
Aug 31, 2026
Emyria Limited reported a sharp increase in revenue for the year ended 30 June 2026, with income from customer sales and clinical services rising 191% to $4.05 million and total revenue reaching $4.34 million. Despite this growth, the group’...
Emyria Sets 2026 AGM Date and Highlights Psychedelic Therapy Risks
Aug 31, 2026
Emyria Limited has scheduled its 2026 annual general meeting for 2.00pm WST on 12 November 2026 at Stantons International in West Perth, with director re-elections on the agenda. The company has set 24 September 2026 as the deadline for director n...
Emyria Moves to Expand Psychedelic Treatment Capacity Ahead of Q4
Aug 20, 2026
Emyria has resolved authorised prescriber capacity constraints across its Perth and Queensland mental health clinics, removing a key bottleneck to expanding psychedelic-assisted treatment services. With prescribing approvals in place, the limiting...
Emyria Options Lapse, Trimming Potential Share Dilution
Aug 16, 2026
Emyria Ltd, listed on the ASX under ticker EMD, lodged an Appendix 3H notice detailing changes to its issued capital. The company advised that a class of options tied to its securities has reached expiry and no longer forms part of its outstanding...
Emyria relocates head office as it advances psychedelic-assisted therapy programs
Aug 10, 2026
Emyria Limited, an Australian mental health and neurological treatment developer, combines evidence-based clinical services, real-world data gathering, and a pipeline of psychedelic-assisted therapies and drug candidates. Its Emyria Healthcare div...
Emyria accelerates national Empax rollout as revenues surge and clinical data impress
Jul 29, 2026
Emyria reported quarterly revenue of about $1.53 million and FY26 revenue of approximately $4.3 million, more than double the prior year, driven by clinic growth and insurer-funded patient demand. The company’s Victorian Empax clinic on the ...
Emyria invites investors to quarterly update amid progress in experimental mental health therapies
Jul 29, 2026
Emyria Limited has invited investors to a quarterly webinar on 30 July 2026, where Executive Chairman Greg Hutchinson and Chief Operating Officer Mary-Ann Rennie will discuss the company’s June 2026 activities and outline expectations for th...
Emyria underscores risks and regulatory hurdles in psychedelic mental health therapies
Jul 26, 2026
Emyria has outlined its role in developing and delivering advanced mental health therapies, emphasising psychedelic-assisted psychotherapy using MDMA, psilocybin and MDMA-inspired compounds in tightly controlled clinical settings. The company stre...
Emyria to Present on Innovative Mental Health Care at Sydney Summit
Jul 21, 2026
Emyria Ltd, a leader in intensive, evidence-based mental health care, will showcase its growing expertise in innovative treatment models at a sector-focused event in Sydney next month. The ASX-listed company’s work spans preventative initiat...
Emyria posts encouraging early data from treatment-resistant depression program
Jun 24, 2026
Emyria has reported encouraging early data from its second major treatment program targeting treatment-resistant depression, with all 10 patients in the first cohort showing statistically and clinically significant reductions in depression and tra...
Emyria Trains NSW Clinicians Ahead of First Sydney Empax Clinic Opening
Jun 21, 2026
Emyria has completed training for its first cohort of New South Wales clinicians, with 25 therapists and six psychiatrists prepared to staff its inaugural Sydney Empax clinic at Matilda Nepean. These practitioners join a national network of more t...
Emyria releases investor video update on evolving psychedelic treatment strategy
Jun 16, 2026
Emyria Limited, a leader in innovative mental health treatments, combines clinical services, real-world data collection and a development pipeline targeting psychedelic-assisted therapies and novel drugs for mental health and neurological diseases...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.